Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

3 papers

Ayahuasca for Sadness or low mood

Based on 15 papers

Research on ayahuasca for sadness and low mood shows promise but is still early. Lab and animal studies suggest its active ingredient, DMT, can change brain connections. Small human trials and patient reports find mood improvements for some people, especially in hard-to-treat depression. However, most clinical studies are small or preliminary. Safety, who the results apply to, and exactly how the brew helps are not settled. Scientists say more large, careful trials with diverse participants and good medical oversight are needed.

Key findings

  • Ayahuasca is a traditional plant brew. One plant provides DMT and the other has chemicals that stop the body from breaking DMT, so the DMT works when you drink it (not just when injected or smoked). 15082 15059
  • In lab and animal studies, DMT and related compounds can make neurons grow new branches and form more connections, which could help change mood. But some animal studies found different effects depending on dose or sex, so results are not uniform. 15050 15082
  • Small clinical studies and early human trials report reductions in depression symptoms after ayahuasca or DMT treatments, with the strongest and most consistent promise for treatment‑resistant major depression so far. 15082 15060 15063
  • Overall evidence in humans is still limited. Many trials are small or early‑stage, so researchers say larger and better‑controlled studies are needed before firm conclusions can be drawn. 15082 15063 15085
  • Patients often describe helpful psychological processes such as personal insight, a changed sense of self, and feeling more connected to others. These kinds of experiences — plus preparation and therapy before and after the session — are strongly linked to better outcomes. 15092 15063 15091
  • Safety matters. Reviews and experts stress the need for medical oversight, careful set and setting, and follow‑up care. The growing psychedelic industry also raises ethical and legal questions that affect how treatments are delivered. 15091 15085 15082
  • A large review of many psychoplastogen studies found no clear rise in blood levels of BDNF (a protein sometimes linked to brain change) after these drugs. That suggests blood BDNF may not be a reliable marker of how these drugs affect the human brain. 15129
  • Most past psychedelic therapy studies included mostly White participants. Because ayahuasca comes from Indigenous traditions and people of color were underrepresented in research, study results may not apply to all cultural or ethnic groups. 15095 15058 15082

The Emerging Field of Psychedelic Psychotherapy

Gregory Barber, Scott T. Aaronson
Current Psychiatry Reports Summary & key facts 2022 48 citations

This review looks at recent research where drugs like MDMA and psilocybin are given inside carefully run therapy programs. People get hours of preparation, one or more drug sessions, and several follow-up therapy sessions to help make sense of the experience. Trials so far show big improvements for some people…

Chemical synthesis and alkaloids Diverse academic research themes Psychedelics and Drug Studies Ayahuasca Ibogaine

Effects of Psychedelics in Older Adults: A Prospective Cohort Study

Hannes Kettner, Leor Roseman, Adam Gazzaley, Robin Carhart‐Harris, Lorenzo Pasquini

Researchers followed 62 older adults (age 60 and up) and 62 younger adults who planned to take part in guided psychedelic group sessions. People in both age groups reported better well-being in the weeks after the sessions, but older adults experienced weaker immediate drug effects during the sessions. For older…

Biochemical Analysis and Sensing Techniques Chemical synthesis and alkaloids Psychedelics and Drug Studies Ayahuasca LSD

Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders

Nataliya S. Vorobyeva, Alena A. Kozlova
Frontiers in Pharmacology Summary & key facts 2022 14 citations

This paper reviews research on three naturally occurring psychedelics: psilocybin, ibogaine, and N,N-dimethyltryptamine (the active part of the brew ayahuasca). It explains that these drugs work on the brain's serotonin system and summarizes growing studies that suggest they might help with problems like post-traumatic stress disorder, major depression, anxiety, and…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca Ibogaine
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.